Viral oncolysis

Oncologist

Volumn 7, Issue 2, 2002, Pages 106-119

  Mullen, John T ^a   Tanabe, Kenneth K ^a,b,c  

^a Division of Surgical Oncology   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical trials; Gene therapy; Oncolysis; Replication conditional viruses

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CYTOLYSIS; HERPES SIMPLEX VIRUS; HUMAN; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; REOVIRUS; TUMOR CELL; VACCINATION; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; DNA, VIRAL; GENE THERAPY; GENOME, VIRAL; HUMANS; NEOPLASMS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUSES;

EID: 0036224352     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-2-106     Document Type: Article

References (90)

1. Rabies virus vaccination in a patient with cervical carcinoma
2. Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica
3. New developments in the virus therapy of cancer: A historical review
4. Studies on the use of viruses in the treatment of carcinoma of the cervix
5. Virus treatment in advanced cancer
6. Pathogenicity and oncolytic capacity of RI virus strain RI-67 in man
7. Newcastle disease virus as an antineoplastic agent
8. Replicating oncolytic viruses: An overview
9. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants
10. Adenovirus type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells
11. Regulation of TNF-mediated cell death and inflammation by human adenoviruses
12. Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity
13. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells
14. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial
15. p53 status and the efficacy of cancer therapy in vivo
16. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene
17. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
18. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
19. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
20. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
21. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
22. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
23. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
24. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
25. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015)
26. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
27. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
28. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma
29. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy
30. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus
31. Immunotherapy of malignant melanoma with vaccinia virus
32. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate
33. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells
34. Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product
35. Inhibition of p53 transactivation required for transformation by adenovirus early EIB protein
36. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
37. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
38. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status
39. EIB-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors
40. Intra-arterial administration of a replication-selective adenovirus Ci-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biological activity
41. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial
42. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)
43. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
44. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
45. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts
46. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
47. Conditionally replicating herpes vectors for cancer therapy
48. Experimental therapy of human glioma by means of a genetically engineered virus mutant
49. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus
50. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
51. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas
52. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
53. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
54. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
55. Oncolytic herpes simplex virus-I lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer
56. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1
57. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
58. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents
59. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
60. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses
61. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model
62. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells
63. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
64. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors
65. Transcriptional targeting of herpes simplex virus for cell-specific replication
66. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo
67. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma
68. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
69. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxaza-phosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies
70. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus
71. Prodrug bioactivation and oncolysis of diffuse liver metastases by an HSV1 mutant virus that expresses the CYP2B1 transgene
72. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes
73. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
74. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
75. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression
76. A mutant vaccinia virus with improved tumor selectivity
77. The preferential cytotoxicity of reovirus for certain transformed cell lines
78. Differential sensitivity of normal and transformed human cells to reovirus infection
79. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus
80. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency
81. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection
82. Reovirus therapy of tumors with activated Ras pathway
83. Reovirus therapy of metastatic cancer models in immune-competent mice
84. Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo
85. Newcastle disease virus selectively kills human tumor cells
86. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy
87. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire
88. PV701, a naturally attenuated strain of Newcastle disease virus, has a broad spectrum of oncolytic activity against human tumor xenografts
89. Regression of human tumor xenografts following intravenous treatment using PV701, a naturally attenuated oncolytic strain of Newcastle disease virus
90. An intravenous phase I trial of a replication-competent virus, PV701, in the treatment of patients with advanced solid cancers